Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate LENZ Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding LENZ Therapeutics, Inc.’s stock price such as:

• LENZ Therapeutics, Inc.’s current stock price and volume
• Why LENZ Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for LENZ from analysts
• LENZ’s stock price momentum as measured by its relative strength

About LENZ Therapeutics, Inc. (LENZ)

Before we jump into LENZ Therapeutics, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Want to learn more about LENZ Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about LENZ Therapeutics, Inc..

LENZ Therapeutics, Inc.’s Stock Price as of Market Close

As of August 10, 2026, 4:00 PM, CST, LENZ Therapeutics, Inc.’s stock price was $5.360.

LENZ Therapeutics, Inc. is 0% from its previous closing price of $5.360.

During the last market session, LENZ Therapeutics, Inc.’s stock traded between $5.290 and $5.480. Currently, there are approximately 31.35 million shares outstanding for LENZ Therapeutics, Inc..

LENZ Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

LENZ Therapeutics, Inc. Stock Price History

LENZ Therapeutics, Inc.’s (LENZ) price is currently up 1.13% so far this month.

During the month of August, LENZ Therapeutics, Inc.’s stock price has reached a high of $5.480 and a low of $4.920.

Over the last year, LENZ Therapeutics, Inc. has hit prices as high as $50.400 and as low as $4.680. Year to date, LENZ Therapeutics, Inc.’s stock is down 66.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused LENZ Therapeutics, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 07, 2026, there was 1 analyst who downgraded LENZ Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate LENZ Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on LENZ Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

LENZ Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about LENZ Therapeutics, Inc. (LENZ) by visiting AAII Stock Evaluator.

Relative Price Strength of LENZ Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 07, 2026, LENZ Therapeutics, Inc. has a weighted four-quarter relative price strength of -40.90%, which translates to a Momentum Score of 3 and is considered to be Very Weak.

Want to learn more about how LENZ Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

LENZ Therapeutics, Inc. Stock Price: Bottom Line

As of August 10, 2026, LENZ Therapeutics, Inc.’s stock price is $5.360, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like LENZ Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.